NO20005884L - Kombinasjonsterapi for behandling av bipolare forstyrrelser - Google Patents

Kombinasjonsterapi for behandling av bipolare forstyrrelser

Info

Publication number
NO20005884L
NO20005884L NO20005884A NO20005884A NO20005884L NO 20005884 L NO20005884 L NO 20005884L NO 20005884 A NO20005884 A NO 20005884A NO 20005884 A NO20005884 A NO 20005884A NO 20005884 L NO20005884 L NO 20005884L
Authority
NO
Norway
Prior art keywords
treatment
combination therapy
bipolar disorders
bipolar
disorders
Prior art date
Application number
NO20005884A
Other languages
English (en)
Other versions
NO20005884D0 (no
Inventor
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20005884D0 publication Critical patent/NO20005884D0/no
Publication of NO20005884L publication Critical patent/NO20005884L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
NO20005884A 1998-05-29 2000-11-21 Kombinasjonsterapi for behandling av bipolare forstyrrelser NO20005884L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8712698P 1998-05-29 1998-05-29
PCT/US1999/011314 WO1999062522A1 (en) 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders

Publications (2)

Publication Number Publication Date
NO20005884D0 NO20005884D0 (no) 2000-11-21
NO20005884L true NO20005884L (no) 2001-01-24

Family

ID=22203275

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005884A NO20005884L (no) 1998-05-29 2000-11-21 Kombinasjonsterapi for behandling av bipolare forstyrrelser

Country Status (19)

Country Link
EP (1) EP0966967A3 (no)
JP (1) JP2002516864A (no)
KR (1) KR20010043731A (no)
CN (1) CN1302207A (no)
AU (1) AU756468B2 (no)
BR (1) BR9911068A (no)
CA (1) CA2332408A1 (no)
CZ (1) CZ20004280A3 (no)
EA (1) EA003611B1 (no)
HR (1) HRP20000798A2 (no)
HU (1) HUP0102511A2 (no)
IL (1) IL139591A0 (no)
NO (1) NO20005884L (no)
NZ (1) NZ507981A (no)
PL (1) PL344304A1 (no)
SK (1) SK17492000A3 (no)
TR (1) TR200003525T2 (no)
WO (1) WO1999062522A1 (no)
ZA (1) ZA200006817B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
JP2002530339A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． ２−ヒドロキシメチルオランザピン組成物及び方法
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
NZ526801A (en) 2001-01-02 2005-07-29 Upjohn Co Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system
CA2445528A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
US7973043B2 (en) 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
WO2004047727A2 (en) 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
NZ540054A (en) 2002-12-27 2007-09-28 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
CN1780626A (zh) * 2003-05-16 2006-05-31 辉瑞产品公司 双相性精神障碍和相关症状的治疗
LT1626721T (lt) * 2003-05-23 2017-01-25 Otsuka Pharmaceutical Co., Ltd. Karbostirilo dariniai ir nuotaikos stabilizatoriai, skirti nuotaikos sutrikimų gydymui
WO2005053703A1 (en) * 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
JP2007513896A (ja) * 2003-12-15 2007-05-31 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
CA2569411A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US20080199866A1 (en) * 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用
CN110151718A (zh) * 2019-06-13 2019-08-23 厦门医学院 一种奥氮平口腔崩解片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
CN1213966A (zh) * 1996-03-11 1999-04-14 伊莱利利公司 治疗两极紊乱的方法
AU725556B2 (en) * 1996-03-25 2000-10-12 Eli Lilly And Company Method for treating pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
TR200003525T2 (tr) 2001-04-20
NO20005884D0 (no) 2000-11-21
CZ20004280A3 (cs) 2001-09-12
CN1302207A (zh) 2001-07-04
WO1999062522A1 (en) 1999-12-09
EP0966967A3 (en) 2000-05-31
HRP20000798A2 (en) 2001-10-31
PL344304A1 (en) 2001-10-22
CA2332408A1 (en) 1999-12-09
BR9911068A (pt) 2001-02-06
EA003611B1 (ru) 2003-06-26
EA200001244A1 (ru) 2001-06-25
IL139591A0 (en) 2002-02-10
SK17492000A3 (sk) 2002-04-04
HUP0102511A2 (hu) 2001-11-28
JP2002516864A (ja) 2002-06-11
NZ507981A (en) 2003-10-31
AU756468B2 (en) 2003-01-16
AU4008899A (en) 1999-12-20
EP0966967A2 (en) 1999-12-29
ZA200006817B (en) 2002-02-21
KR20010043731A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
NO991381L (no) Kombinasjonsterapi for behandling av psykoser
NO993051D0 (no) Intranasale formuleringer for behandling av seksuelle forstyrrelser
NO20010882L (no) Terapier for behandling av lungesykdommer
NO951761D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
HUP0201791A2 (en) The use of escitalopram for treatment of neurotic disorders
NO20010456L (no) Triazolopyridiner for behandling av trombose lidelser
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
NO984432D0 (no) FremgangsmÕte for behandling av migrenesmerte
NO20011892L (no) 3-tetrahydropyridin-4-yl-indoler for behandling av psykotiske forstyrrelser
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
NO20010390D0 (no) Behandling av angstsykdommer
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
IS6020A (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ATE204167T1 (de) Antikonvulsive derivate zur behandlung von psoriasis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application